Vanguard Group Inc. lowered its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 7.4% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 4,812,955 shares of the company’s stock after selling 384,612 shares during the quarter. Vanguard Group Inc. owned 0.11% of Pacira BioSciences worth $124,559,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of PCRX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Pacira BioSciences by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,242 shares of the company’s stock valued at $677,000 after buying an additional 1,165 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Pacira BioSciences by 49.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company’s stock valued at $27,454,000 after purchasing an additional 367,869 shares during the last quarter. Strs Ohio bought a new position in shares of Pacira BioSciences during the 1st quarter valued at about $75,000. Marshall Wace LLP bought a new position in shares of Pacira BioSciences during the 2nd quarter valued at about $4,550,000. Finally, Sei Investments Co. boosted its holdings in shares of Pacira BioSciences by 35.3% during the 2nd quarter. Sei Investments Co. now owns 25,357 shares of the company’s stock valued at $606,000 after purchasing an additional 6,609 shares during the last quarter. Institutional investors own 99.73% of the company’s stock.
Pacira BioSciences Price Performance
PCRX opened at $22.84 on Wednesday. The business has a fifty day moving average of $23.37 and a 200 day moving average of $23.19. Pacira BioSciences, Inc. has a 52-week low of $18.80 and a 52-week high of $27.64. The company has a quick ratio of 3.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.56. The stock has a market cap of $898.75 million, a P/E ratio of 190.35 and a beta of 0.32.
Analyst Ratings Changes
Several research analysts recently commented on the company. Barclays dropped their price target on Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating for the company in a research report on Thursday, March 26th. Zacks Research upgraded Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 7th. Royal Bank Of Canada lifted their price target on Pacira BioSciences from $22.00 to $24.00 and gave the stock a “sector perform” rating in a research report on Friday, May 1st. Wall Street Zen lowered Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Finally, Needham & Company LLC lifted their price target on Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, May 1st. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Pacira BioSciences has an average rating of “Hold” and a consensus price target of $29.40.
Check Out Our Latest Analysis on Pacira BioSciences
Insiders Place Their Bets
In other Pacira BioSciences news, CFO Shawn Cross sold 12,941 shares of the stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $25.16, for a total value of $325,595.56. Following the sale, the chief financial officer owned 105,341 shares in the company, valued at $2,650,379.56. This trade represents a 10.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jonathan Slonin sold 3,261 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $22.82, for a total value of $74,416.02. Following the completion of the sale, the insider owned 223,640 shares in the company, valued at approximately $5,103,464.80. The trade was a 1.44% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 28,261 shares of company stock worth $702,610. Insiders own 6.40% of the company’s stock.
Pacira BioSciences Company Profile
Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.
In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.
Featured Articles
- Five stocks we like better than Pacira BioSciences
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report).
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
